83 related articles for article (PubMed ID: 17068634)
1. [Advances in study of murine double minute 2/p53 passway with breast cancer].
Ba YH; Li HP
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):551-4. PubMed ID: 17068634
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.
Agrawal A; Yang J; Murphy RF; Agrawal DK
Exp Mol Pathol; 2006 Oct; 81(2):115-22. PubMed ID: 16919268
[TBL] [Abstract][Full Text] [Related]
4. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.
Schmitz KJ; Grabellus F; Callies R; Wohlschlaeger J; Otterbach F; Kimmig R; Levkau B; Schmid KW; Baba HA
Virchows Arch; 2006 Jan; 448(1):16-23. PubMed ID: 16208531
[TBL] [Abstract][Full Text] [Related]
5. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
6. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
7. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
8. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
9. Subcellular localization of Mdm2 expression and prognosis of breast cancer.
Park HS; Park JM; Park S; Cho J; Kim SI; Park BW
Int J Clin Oncol; 2014 Oct; 19(5):842-51. PubMed ID: 24292333
[TBL] [Abstract][Full Text] [Related]
10. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
11. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
12. p53 expression and relationship with MDM2 amplification in breast carcinomas.
Buyukpinarbasili N; Gucin Z; Ersoy YE; İlbak A; Kadioglu H; Muslumanoglu M
Ann Diagn Pathol; 2016 Apr; 21():29-34. PubMed ID: 27040927
[TBL] [Abstract][Full Text] [Related]
13. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice.
Ko J; Shin SM; Oh YM; Lee YS; Ryoo ZY; Lee YH; Na DS; Kim JW
Oncogene; 2004 Mar; 23(10):1950-3. PubMed ID: 14691448
[TBL] [Abstract][Full Text] [Related]
15. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
[TBL] [Abstract][Full Text] [Related]
16. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
17. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
19. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]